Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Wilner

Urology Plano, TX Medical Doctor

NPI 1245284785 CMS profile 55774

6124 W. Parker Rd, Suite 434, Plano, TX 75093

Open in the dashboard

General payments

$3,410

75 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$63,149 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Matthew Wilner of Plano, TX is reported in the CMS Open Payments database as having received $3,410 across 75 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $63,149 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 55th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $229 8
2024 General $143 6
2023 General $117 6
2022 General $1,324 17
2021 General $203 12
2020 General $939 10
2019 General $455 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Wilner
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Matthew Wilner were reported at $229. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Matthew Wilner Urology median Middle half National median
2019 $455 $480 $147–$1,201 $163
2020 $939 $246 $87–$645 $114
2021 $203 $358 $111–$1,000 $132
2022 $1,324 $476 $143–$1,263 $149
2023 $117 $560 $168–$1,461 $160
2024 $143 $563 $170–$1,464 $164
2025 $229 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Teleflex LLC $1,018 4 payments
  2. NeoTract Inc. $874 7 payments
  3. Pfizer Inc. $215 11 payments
  4. Astellas Pharma US Inc $213 12 payments
  5. Boston Scientific Corporation $166 3 payments
  6. Dendreon Pharmaceuticals LLC $139 7 payments
  7. Innovation Technologies Inc $97 3 payments
  8. Janssen Biotech, Inc. $85 1 payment
  9. Olympus America Inc. $83 3 payments
  10. TOLMAR Pharmaceuticals, Inc. $67 2 payments
  11. Other $451 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,913 67 payments
  2. Travel and Lodging $1,352 5 payments
  3. Education $144 3 payments
Products named General payments · program years 2019–2025
  1. UROLIFT $1,892 11 payments
  2. XTANDI $407 22 payments
  3. ORGOVYX $168 9 payments
  4. REZUM $147 2 payments
  5. PROVENGE $139 7 payments
  6. Irrisept $97 3 payments
  7. MYRBETRIQ $87 4 payments
  8. ERLEADA $85 1 payment
  9. iTIND System $83 3 payments
  10. ELIGARD $67 2 payments
  11. Other $541 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

3,954

Median for Urology: 1,053

Drug cost

$3,684,138

Median for Urology: $101,464

Branded share of claims

27.7%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtandi Enzalutamide Brand 180 $2,446,430
Erleada Apalutamide Brand 30 $433,489
Nubeqa Darolutamide Brand 18 $237,385
Orgovyx Relugolix Brand 82 $216,307
Myrbetriq Mirabegron Brand 218 $188,651
Gemtesa Vibegron Brand 24 $31,446
Methenamine Hippurate Generic 184 $22,249
Tamsulosin Hcl Generic 1,125 $18,451
Mirabegron Er Mirabegron Brand 21 $15,470
Abiraterone Acetate Generic 12 $12,264

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 133 billing codes

Paid by Medicare

$719,805

Of which drugs: $292,651

Medicare patients

1,238

Average age 77

Services billed

32,182

167 women, 1,071 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 45%
Ischemic heart disease 34%
Cancer 33%
Diabetes 27%
Chronic kidney disease 27%
Atrial fibrillation 24%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 35 294 $40,913
Injection, testosterone cypionate, 1 mg J1071 Office 12 14,900 $240
Injection, garamycin, gentamicin, up to 80 mg J1580 Office 33 71 $132

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
PROVENGE
  • Dendreon Pharmaceuticals LLC $34
$34 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

75 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record